What is the clinical significance of an Epstein-Barr virus viral capsid antigen IgG result reported as less than 36 U/mL?

EBV Viral Capsid Antigen <36.00 U/mL: Clinical Interpretation

A VCA result below 36 U/mL indicates the absence of detectable IgG antibodies to EBV viral capsid antigen, which most commonly means the patient has never been infected with Epstein-Barr virus and remains susceptible to primary infection.

Understanding the Result

This negative VCA-IgG result has several possible interpretations depending on clinical context:

Most Likely Scenario: No Prior EBV Exposure

• The patient is EBV-naïve (seronegative) and has never encountered the virus
• Approximately 5-10% of adults remain EBV-negative throughout life
• These individuals remain at risk for primary infection (infectious mononucleosis) if exposed

Alternative Scenarios to Consider

Very Early Primary Infection (Window Period)

• If symptoms suggest acute mononucleosis but VCA-IgG is negative, the patient may be in the earliest phase of infection (first 1-2 weeks)
• VCA-IgM typically appears first, followed by VCA-IgG within days to weeks 1
• Action required: Check VCA-IgM and repeat VCA-IgG in 1-2 weeks if clinical suspicion is high

Severe Immunocompromise

• Profoundly immunosuppressed patients may fail to mount antibody responses
• Consider in patients with HIV/AIDS, chemotherapy, or immunosuppressive therapy
• These patients may have active EBV infection despite negative serology 2

Clinical Decision Algorithm

If patient is symptomatic (fever, pharyngitis, lymphadenopathy):

1. Order complete EBV panel: VCA-IgM, VCA-IgG, EBNA-1 IgG 1
2. If all negative → consider alternative diagnoses (CMV, acute HIV, streptococcal pharyngitis)
3. If VCA-IgM positive with negative VCA-IgG → likely acute primary infection in window period; repeat VCA-IgG in 7-14 days

If patient is asymptomatic (screening context):

• Document seronegative status
• Counsel about susceptibility to primary infection
• No further testing needed unless future exposure or symptoms develop

Key Diagnostic Considerations

The interpretation of EBV serology requires understanding the complete antibody pattern 1. A negative VCA-IgG alone is insufficient for diagnosis in symptomatic patients. The evidence demonstrates that parallel testing of VCA-IgM, VCA-IgG, and EBNA-1 IgG is necessary for conclusive results 3, as the serological response can be highly variable.

For chronic active EBV infection (CAEBV), diagnostic guidelines specify that patients typically have elevated VCA-IgG titers (≥1:640) along with elevated EA-IgG 4. A negative VCA result effectively excludes CAEBV.

Common Pitfalls to Avoid

• Do not assume negative serology excludes acute infection in the first week of symptoms—VCA-IgG may not yet be detectable
• Do not order isolated VCA testing without the complete panel (IgM, IgG, EBNA-1) in symptomatic patients, as this leads to misinterpretation in >30% of cases 1
• Do not rely solely on serology in immunocompromised patients—consider EBV PCR/viral load testing if clinical suspicion exists 2